EP1377312A4 - LETHAL FACTOR OF ANTHRAX INHIBITING TUMOR GROWTH AND ANGIOGENESIS - Google Patents

LETHAL FACTOR OF ANTHRAX INHIBITING TUMOR GROWTH AND ANGIOGENESIS

Info

Publication number
EP1377312A4
EP1377312A4 EP02725277A EP02725277A EP1377312A4 EP 1377312 A4 EP1377312 A4 EP 1377312A4 EP 02725277 A EP02725277 A EP 02725277A EP 02725277 A EP02725277 A EP 02725277A EP 1377312 A4 EP1377312 A4 EP 1377312A4
Authority
EP
European Patent Office
Prior art keywords
anthrax
angiogenesis
tumor growth
inhibiting tumor
lethal factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02725277A
Other languages
German (de)
French (fr)
Other versions
EP1377312A1 (en
Inventor
Nicholas S Duesbery
Craig P Webb
Woude George F Vande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VAN ANDEL INSTITUTE
ANDEL INST VAN
Original Assignee
VAN ANDEL INSTITUTE
ANDEL INST VAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VAN ANDEL INSTITUTE, ANDEL INST VAN filed Critical VAN ANDEL INSTITUTE
Publication of EP1377312A1 publication Critical patent/EP1377312A1/en
Publication of EP1377312A4 publication Critical patent/EP1377312A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02725277A 2001-03-22 2002-03-22 LETHAL FACTOR OF ANTHRAX INHIBITING TUMOR GROWTH AND ANGIOGENESIS Withdrawn EP1377312A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27762501P 2001-03-22 2001-03-22
US277625P 2001-03-22
PCT/US2002/008656 WO2002076496A1 (en) 2001-03-22 2002-03-22 Anthrax lethal factor inhibits tumor growth and angiogenesis

Publications (2)

Publication Number Publication Date
EP1377312A1 EP1377312A1 (en) 2004-01-07
EP1377312A4 true EP1377312A4 (en) 2004-10-06

Family

ID=23061685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02725277A Withdrawn EP1377312A4 (en) 2001-03-22 2002-03-22 LETHAL FACTOR OF ANTHRAX INHIBITING TUMOR GROWTH AND ANGIOGENESIS

Country Status (4)

Country Link
EP (1) EP1377312A4 (en)
AU (1) AU2002255852B2 (en)
CA (1) CA2442015A1 (en)
WO (1) WO2002076496A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8856201A (en) * 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
WO2004100978A1 (en) * 2003-05-13 2004-11-25 Medvet Science Pty. Ltd. A method of modulating cellular transmigration and agents for use therein
DE602004024536D1 (en) * 2003-07-07 2010-01-21 Van Andel Res Inst INHIBITION OF TUMOR ANGIOGENESIS BY A COMBINATION OF THROMBOSPONDIN-1 AND INHIBITORS OF THE VASCULAR ENDOTHEL GROWTH FACTOR
WO2005040098A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
UA89035C2 (en) * 2003-12-03 2009-12-25 Лео Фарма А/С Hydroxamic acid esters and pharmaceutical use thereof
AT504159A1 (en) 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
WO2009132397A1 (en) * 2008-05-01 2009-11-05 University Of South Australia Methods and agents for modulating the level and/or activity of hif-2 alpha protein
EP2701694A4 (en) 2011-04-28 2014-10-08 Univ Duke METHODS OF TREATING HEMOGLOBINOPATHIES
WO2013082511A1 (en) * 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
US9861685B2 (en) 2012-11-20 2018-01-09 Duke University Methods of treating hemoglobinopathies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
GB2323845A (en) * 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
NZ501276A (en) * 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
EP1066401A2 (en) * 1998-04-01 2001-01-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Anthrax lethal factor is a mapk kinase protease
PL348326A1 (en) * 1998-12-22 2002-05-20 Warner Lambert Co Combination chemotherapy
HUP0105092A3 (en) * 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
EP1144372B1 (en) * 1999-01-13 2005-11-30 Warner-Lambert Company Llc Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
CA2362380A1 (en) * 1999-03-19 2000-09-28 Bristol-Meyers Squibb Pharma Company Amino-thio-acrylonitriles as mek inhibitors
WO2000056725A1 (en) * 1999-03-19 2000-09-28 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'-[4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 306a, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2000 (2000-11-16), BONATI ANTONIO ET AL: "Selective inhibition of MEK1 kinase downmodulates ERK activity and proliferation of AML blasts", XP002279051, Database accession no. PREV200100301863 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; October 1999 (1999-10-01), PRICE DAVID T ET AL: "Activation of extracellular signal-regulated kinase in human prostate cancer", XP002279050, Database accession no. PREV199900481092 *
JOURNAL OF UROLOGY, vol. 162, no. 4, October 1999 (1999-10-01), pages 1537 - 1542, ISSN: 0022-5347 *
See also references of WO02076496A1 *

Also Published As

Publication number Publication date
EP1377312A1 (en) 2004-01-07
AU2002255852B2 (en) 2006-11-09
CA2442015A1 (en) 2002-10-03
WO2002076496A1 (en) 2002-10-03

Similar Documents

Publication Publication Date Title
FR20C1039I2 (en) DERIVATIVES OF UK-2A
EP1385862A4 (en) VICTORY ENDOTH LIAL GROWTH FACTOR 2
EP1432527A4 (en) BIOLOGICAL REGULATION OF NANOPARTICLES
DE69822669D1 (en) REDUCTION OF HAIR GROWTH
EP1037641A4 (en) BAIT OF THE TRANSLATION FACTOR AND TUMOR GROWTH INHIBITOR
EP1357809A4 (en) HYGIENIZATION OF FOODS
FR2831769B1 (en) APPEARANCE FACTOR AND TASTEFAST
CY2006003I2 (en) USE OF DAPTOMYCIN
EP1420807A4 (en) PROTECTION OF THE GROWTH FACTOR DERIVED FROM MYOCARDIAL PLAQUETTES
DE69934510D1 (en) REDUCTION OF HAIR GROWTH
EP1377312A4 (en) LETHAL FACTOR OF ANTHRAX INHIBITING TUMOR GROWTH AND ANGIOGENESIS
HUP0401589A3 (en) New peptides - analogs of human growth hormone-releasing hormone
EP1276713A4 (en) INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
PT1401283E (en) Biological control of plant diseases
EP1100887A4 (en) GROWTH DIFFERENTIATION FACTOR 11
NO20034972L (en) Treatment of ADHD
NO20035668D0 (en) Anti-tumor formulations of thioxanthenone
GB0410147D0 (en) Human angiomotin-like protein 1
TW499838U (en) Improved structure of water-absorbent flowerpot
TW516367U (en) Structure improvement of double-layered water-storage-type flowerpot
AU2001250405A1 (en) Regulation of human adp-ribosylation factor-related protein
GB0415327D0 (en) Human prostrate cancer candidate protein 1
FI20010739A0 (en) Body for spraying heat and moisture
IT1313641B1 (en) EQUIPMENT FOR SPIRALING OF FLOWER AND SIMILAR STEMS.
ITMI20011074A0 (en) DRYING SYSTEM FOR PLANTS FOR THE PRODUCTION OF "TISSUE" PAPER AND SIMILAR

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031007

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040823

17Q First examination report despatched

Effective date: 20080320

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091001